8-K: Flyte Aviation Reduces Preferred Stock Conversion Price

Flyte Aviation, Inc. announced a significant reduction in the conversion price for multiple series of its convertible preferred stock, impacting future common stock dilution.

Summary

• Flyte Aviation, Inc. (formerly Catheter Precision, Inc.) has entered into an agreement for an additional investment of $2.05 million through the purchase of 2,050 shares of Series C-4 Convertible Preferred Stock at $1,000 per share.
• The closing for this investment is anticipated around October 13, 2026, subject to standard closing conditions.
• Each Series C-4 Preferred Stock share is convertible into common stock at a reduced price of $1.00 per share, with potential for up to 2,050,000 shares of common stock.
• The company also reduced the conversion price for its outstanding Series C-1, C-2, C-3, C-4, and Series D Convertible Preferred Stock from $2.30 per share to $1.00 per share.
• Additionally, the conversion price for Series J Convertible Preferred Stock was reduced to $1.00 per share, as approved by stockholders on September 30, 2026.
• These reductions apply to newly issued Series C-4 shares and previously issued shares, impacting potential future dilution.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative development due to significant dilution and a reduction in the effective conversion price of preferred stock, signaling potential financial distress or a need for capital.

Positives

• Secured an additional $2.05 million in gross proceeds through the sale of Series C-4 Convertible Preferred Stock.
• The conversion price reduction to $1.00 per share may make the conversion into common stock more attractive for existing preferred stockholders.

Negatives

• Significant reduction in the conversion price for multiple series of preferred stock from $2.30 to $1.00 per share, indicating a substantial decrease in the perceived value of the common stock.
• The conversion of Series C-4 Preferred Stock at $1.00 per share will result in the issuance of up to 2,050,000 shares of common stock, leading to substantial dilution for existing common shareholders.
• The resale of common stock issuable from the conversion of Series J Convertible Preferred Stock at the new lower price has not been registered, classifying them as 'restricted securities'.
• The company's name change from Catheter Precision, Inc. to Flyte Aviation, Inc. suggests a strategic pivot, the success of which is yet to be determined.

Risks

• Potential for significant dilution of common stock due to the reduced conversion prices of various preferred stock series.
• The need for capital raises at significantly lower valuations than previously established, as indicated by the conversion price reduction.
• Unregistered status of additional common stock issuable from Series J Convertible Preferred Stock conversions, posing limitations on their resale.
• The company's reliance on unregistered securities sales (Section 4(a)(2) and Rule 506(b)) for capital raises.

Future Outlook

The filing indicates ongoing capital raising activities and significant adjustments to preferred stock terms, suggesting a focus on securing funding. The conversion price reductions imply a challenging outlook for the common stock valuation.

Industry Context

StockSavvy.ai notes that frequent capital raises coupled with significant reductions in conversion prices are often indicative of companies facing financial pressure or seeking to shore up their balance sheets in challenging market conditions. This is particularly relevant in the aviation sector, which can be capital-intensive and subject to economic cycles.

Comparison to Industry Standards

• Industry standards for convertible preferred stock typically involve conversion prices reflecting the company's valuation at the time of issuance. A reduction from $2.30 to $1.00 per share is a substantial decrease, suggesting a significant revaluation or distress.
• Companies in the aviation sector often raise capital through various means, but substantial price reductions on existing convertible instruments can be a red flag compared to companies that maintain stable or increasing valuations.
• The use of Section 4(a)(2) and Regulation D exemptions for sales to accredited investors is common for private placements, but the context of these sales following significant price reductions is noteworthy.

Stakeholder Impact

• Shareholders: Potential for significant dilution of ownership percentage and value of common stock due to the reduced conversion prices and issuance of new shares.
• Investors in Series C-4 Preferred Stock: Will convert into common stock at a lower price, potentially leading to a quicker path to common stock ownership.
• Existing Preferred Stockholders (Series C-1, C-2, C-3, D, J): Benefit from a lower conversion price, making their investment more likely to convert to common stock, but also potentially signaling company distress.

Next Steps

• Closing of the Series C-4 Preferred Stock purchase is expected on or about October 13, 2026.
• The company will continue to operate under its new name, Flyte Aviation, Inc.

Key Dates

Recommendation

The significant reduction in conversion prices for multiple series of preferred stock from $2.30 to $1.00 per share, coupled with an additional capital raise at this lower valuation, strongly suggests that the company's common stock is overvalued or facing significant financial challenges. This indicates a high probability of further downside for common shareholders due to dilution and potential financial distress.

Keywords

Convertible Preferred Stock, Series C-4, Series J, Conversion Price Reduction, Equity Financing, Dilution, Accredited Investors, Restricted Securities